Semaglutide has the largest community of users of any peptide in this database. This article aggregates the most consistent findings from thousands of community experience reports.
The Titration Phase (Weeks 1–8)
The most commonly reported experience during titration is significant appetite suppression, often described as "food noise going quiet." Many users report being surprised by how little they want to eat. Nausea is the most common side effect, typically occurring in the first 4–6 weeks and resolving as the body adapts. The community strongly recommends slow titration to minimize nausea.
Steady State (Months 2–6)
At steady state, the community reports consistent weight loss of 1–2 lbs per week, with total weight loss of 10–20% of body weight over 6–12 months being the most commonly reported outcome. Improved blood sugar control and reduced cravings for ultra-processed foods are also frequently mentioned.
The Physician Supervision Imperative
Semaglutide requires a prescription and physician supervision. Alukard provides comprehensive semaglutide protocols with metabolic assessment, lab monitoring, and ongoing physician oversight — the safest and most effective way to access this compound.